Everything below concerns GHS-R1a. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
=== Lungs === Fibrothorax Pulmonary fibrosis Cystic fibrosis Idiopathic pulmonary fibrosis (idiopathic meaning 'of unknown cause') Radiation-induced lung injury (following radiation therapies commonly used to treat cancer)
Larter has appeared on the cover of numerous magazines including (in alphabetical order) Allure, Cosmopolitan (France, Indonesia, Ecuador, Germany, Greece, Turkey and U.S.), Entertainment Weekly, Esquire, Glamour, Health, InStyle, Lucky, Maxim, Philadelphia Style, Self, Seventeen, and Shape. In June 2010, Larter was one of thousands of delegates from 130 countries who participated in a United Nations conference, Women Deliver in Washington, D.C. Larter, along with her husband Hayes MacArthur, hosted The Art of Elysium Gala in 2013 and they were recipients of the Spirit of Elysium Award at the January 2014 ceremony.
== Gene == The COL2A1 gene is located on the long (q) arm of chromosome 12 between positions 13.11 and 13.2, from base pair 46,653,017 to base pair 46,684,527. The expression of COL2A1 is regulated by SOX-9 and retrotransposon gag-like-3 gene RTL3 in chondrocytes. There are two transcripts identified for this gene.
Collagen receptors are membrane proteins that bind the extracellular matrix protein collagen, the most abundant protein in mammals. They control mainly cell proliferation, migration and adhesion, coagulation cascade activation and they affect ECM structure by regulation of MMP (matrix metalloproteinases). There are at least eight human collagen receptors.
=== Radioactivity === Thorium was first observed to be radioactive in 1898, by the German chemist Gerhard Carl Schmidt and later that year, independently, by the Polish-French physicist Marie Curie. It was the second element that was found to be radioactive, after the 1896 discovery of radioactivity in uranium by French physicist Henri Becquerel. Starting from 1899, the New Zealand physicist Ernest Rutherford and the American electrical engineer Robert Bowie Owens studied the radiation from thorium; initial observations showed that it varied significantly. It was determined that these variations came from a short-lived gaseous daughter of thorium, which they found to be a new element. This element is now named radon, the only one of the rare radioelements to be discovered in nature as a daughter of thorium rather than uranium. After accounting for the contribution of radon, Rutherford, now working with the British physicist Frederick Soddy, showed how thorium decayed at a fixed rate over time into a series of other elements in work dating from 1900 to 1903. This observation led to the identification of the half-life as one of the outcomes of the alpha particle experiments that led to the disintegration theory of radioactivity. The biological effect of radiation was discovered in 1903. The newly discovered phenomenon of radioactivity excited scientists and the general public alike. In the 1920s, thorium's radioactivity was promoted as a cure for rheumatism, diabetes, and sexual impotence.
Sources: en.wikipedia.org
Also was added a five-year minimum mandatory sentence for anyone found in possession of cocaine base, even without evidence of intent to distribute. The penalties applied to citizens even without prior convictions. The vote passed 346–11. Six of the negative votes came from the Congressional Black Caucus.
(2026) report new mitogenomes of at least 7 Neanderthal individuals from the Stajnia Cave (Poland), interpreted as likely dating to Marine Isotope Stage 5, find that the studied individual carried mitochondrial DNA lineages related to those Western Europe and the northern Caucasus, and interpret their findings as possible evidence of a widespread mitochondrial DNA lineage that was subsequently replaced by the mtDNA found in late Neanderthals. Evidence of exploitation of European pond turtles by Neanderthals occupying the Neumark-Nord site (Germany) during the Last Interglacial is presented by Gaudzinski-Windheuser et al. (2026). Palancar et al. (2026) provide evidence of a clear morphological distinction between axes of Neanderthals and modern humans on the basis of the study of a Neanderthal axis from the Sidrón Cave (Spain). Evidence from the study of metacarpal remains from the Sidrón Cave indicative of differences of metacarpal morphology of Neanderthals and modern humans is presented by Rosas et al. (2026). Rodrigo et al. (2026) provide evidence from the study of animal remains from the Fumane Cave (Italy) indicative of a structured subsistence strategy of Neanderthals occupying the site, including processing of carcasses at kill locations and selective transport of high-yield portions of the carcasses into the cave for secondary processing. Burke et al.
Before the introduction of complex nutritional supplements and advances in freeze-dried cultures of LAB, winemakers would cultivate their inoculum of lactic acid bacteria from culture slants provided by laboratories. In the 1960s, these winemakers found it easier to create starter cultures in media that contained apple or tomato juice. This "tomato juice factor" was discovered to be a derivative of pantothenic acid, an important growth factor for the bacteria. As with yeast, oxygen can be considered a nutrient for LAB, but only in very small amount and only for microaerophilic species such as O. oeni. However, no evidence exists currently to suggest that malolactic fermentation runs more smoothly in aerobic conditions than in complete anaerobic conditions, and in fact, excessive amounts of oxygen can retard growth of LAB by favoring conditions of competing microbes (such as Acetobacter).
Platelet-mimicking particles are bioengineered constructs that functionally replicate the size, shape, and mechanical properties of natural platelets, which assist various hemostatic mechanisms. Also known as synthetic platelets, these biosynthetic particles are recent advancements in the field of drug delivery where they enable targeted interactions that enhance hemostasis, minimize bleeding risks, and support localized therapies. Their applications extend to thrombosis, inflammation, and cancer treatment, as well as significant potential in trauma care, cardiovascular therapies, and immunotherapy. They also address limitations of natural platelet transfusions, such as limited availability, short shelf life, and safety concerns. The design and manufacture of platelet-mimicking particles is diverse across current methods and involves precise biomaterial selection, nanoparticle engineering, surface functionalization, and scalable production techniques. Many of these designs include decorating microspheres with specialized antibodies and peptides that can bind to circulating tumor cells and facilitate their removal or altering their shape upon thrombin exposure to accelerate wound healing. Another approach engineers these platelets with a discoidal shape and flexible polymer composition to mimic platelet deformation under shear forces. While these varied approaches aim to optimize surface interactions and hemostatic performance for multiple therapeutic applications, current research on synthetic platelets is primarily in the preclinical stage.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.